Patients with CDX2 expression had better overall and cancer-specific survivals than those without CDX2 expression (HR 0.735, 95% CI 0.599–0.901 and HR 0.574, 95% CI 0.431–0.764, respectively; Table 5). The gene discussed is CDX2; the disease is cancer.